Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Equitix in connection with its acquisition of Brotorp wind park
Mandate

Vinge advises Equitix in connection with its acquisition of Brotorp wind park

February 28, 2020 M&A Energy

Vinge has advised Equitix in conjunction with the acquisition of all shares in Brotorp Power AB, which owns and operates the 46.2 MW Brotorp wind park in Mönsterås Municipality, from BlackRock.

Vinge’s team was headed by M&A partner Peter Sundgren and included, inter alia, partners Johan Cederblad and Thomas Sjöberg (real estate and environment), Christoffer Thalin (M&A); counsel Sofia Törnroth Nyberg (project financing); associates Rasmus Perdahl (M&A), Hannah Kajlinger (M&A), Hannes Pettersson (M&A), Jolinn Uhlin (project financing), Martin Cronsioe (real estate) and Karolina Cohrs (real estate); and project assistant Jessica Öijer.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024